Fig. 2: Neutralization and binding activities of identified potent cross-neutralization antibodies. | Nature Communications

Fig. 2: Neutralization and binding activities of identified potent cross-neutralization antibodies.

From: Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants

Fig. 2

a Neutralization activities of YB9-120, YB12-197, YB13-208, YB9-258, YB13-281, and YB13-292 IgGs towards wildtype, Beta, Delta and Omicron BA.1 pseudoviruses (data are presented as mean values ± SD). n = 2-3. Representative data from at least 2 independent experiments are shown. b Binding curves of YB9-120, YB12-197, YB13-208, YB9-258, YB13-281, and YB13-292 to wildtype, Delta and Omicron spikes are shown. Antibody binding was assessed by biolayer interferometry, IgGs were immobilized onto protein A sensors and binding to spike protein dilution series (200 to 3.125 nM) were recorded, binding kinetics parameters are summarized in Supplementary Table 2. c Effect of common SARS-CoV-2 RBD mutations on YB9-258 and YB13-292 binding. Fold changes are normalized to KDs calculated from binding curves to wildtype RBD (RBD binding curves are shown in Supplementary Fig. 3a, b and KD data used for comparisons are shown in Supplementary Table 3). Source data for a are provided as a Source Data file.

Back to article page